


# Effects of a 5-week intake of erythritol and xylitol on vascular function, abdominal fat and glucose tolerance in humans with obesity: a pilot trial

Valentine Bordier <sup>1,2</sup>, Fabienne Teysseire,<sup>1,2</sup> Jürgen Drewe,<sup>3</sup> Philipp Madörin,<sup>4</sup> Oliver Bieri,<sup>4</sup> Arno Schmidt-Trucksäss,<sup>5</sup> Henner Hanssen,<sup>5</sup> Christoph Beglinger,<sup>2</sup> Anne Christin Meyer-Gerspach,<sup>1,2</sup> Bettina K Wölnerhanssen<sup>1,2</sup>

**To cite:** Bordier V, Teysseire F, Drewe J, *et al.* Effects of a 5-week intake of erythritol and xylitol on vascular function, abdominal fat and glucose tolerance in humans with obesity: a pilot trial. *BMJ Nutrition, Prevention & Health* 2023;0:e000764. doi:10.1136/bmjnph-2023-000764

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjnph-2023-000764>).

For numbered affiliations see end of article.

## Correspondence to

Dr Bettina K Wölnerhanssen; [bettina.woelnerhanssen@unibas.ch](mailto:bettina.woelnerhanssen@unibas.ch)

ACM-G and BKW contributed equally.

Received 30 August 2023  
Accepted 25 October 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

## ABSTRACT

**Introduction** Previous studies in humans and rats suggest that erythritol might positively affect vascular function, xylitol decrease visceral fat mass and both substances improve glycaemic control. The objective of this study was to investigate the impact of a 5-week intake of erythritol and xylitol on vascular function, abdominal fat and blood lipids, glucose tolerance, uric acid, hepatic enzymes, creatinine, gastrointestinal tolerance and dietary patterns in humans with obesity.

**Methods** Forty-two participants were randomised to consume either 36 g erythritol, 24 g xylitol, or no substance daily for 5 weeks. Before and after the intervention, arterial stiffness (pulse wave velocity, arteriolar-to-venular diameter ratio), abdominal fat (liver volume, liver fat percentage, visceral and subcutaneous adipose tissue, blood lipids), glucose tolerance (glucose and insulin concentrations), uric acid, hepatic enzymes, creatinine, gastrointestinal tolerance and dietary patterns were assessed. Data were analysed by linear mixed effect model.

**Results** The 5-week intake of erythritol and xylitol showed no statistically significant effect on vascular function. Neither the time nor the treatment effects were significantly different for pulse wave velocity (time effect:  $p=0.079$ , Cohen's D (95% CI)  $-0.14$  ( $-0.54$ – $0.25$ ); treatment effect:  $p=0.792$ , Cohen's D (95% CI) control versus xylitol:  $-0.11$  ( $-0.61$ – $0.35$ ), control versus erythritol:  $0.05$  ( $0.44$ – $0.54$ ), erythritol versus xylitol:  $0.07$  ( $-0.41$ – $0.54$ )). There was no statistically significant effect on abdominal fat, glucose tolerance, uric acid, hepatic enzymes and creatinine. Gastrointestinal tolerance was good except for a few diarrhoea-related symptoms. Participants of all groups reduced their consumption of sweetened beverages and sweets compared with preintervention.

**Conclusions** The 5-week intake of erythritol and xylitol showed no statistically significant effects on vascular function, abdominal fat, or glucose tolerance in people with obesity.

**Clinical trial registration** NCT02821923.

## INTRODUCTION

Obesity is linked to reduced postprandial incretin secretion<sup>1</sup> and increased glucose

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Prior research indicates that among people with diabetes, erythritol consumption improves glycaemic control and vascular function. Diabetic animal models have demonstrated that both polyols enhance blood glucose control, while xylitol decreases visceral fat mass. In humans, both polyols also trigger the release of metabolically advantageous gastrointestinal hormones (incretins).

## WHAT THIS STUDY ADDS

⇒ This randomised controlled trial in normoglycaemic people with obesity shows no statistically significant effect of a 5-week intake of erythritol and xylitol on vascular function, abdominal fat or glucose tolerance.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The study contributes valuable insights into the metabolic impacts of regular erythritol and xylitol consumption. It reveals that these sugar substitutes do not seem to exhibit adverse effects on vascular function, glycaemic control or fat metabolism and, therefore, hold promise as suitable sugar alternatives for individuals with obesity.

absorption.<sup>2</sup> These characteristics promote hyperglycaemia.<sup>3</sup> Additionally, obesity is associated with increased free fatty acid and triglyceride (TG) concentrations.<sup>4 5</sup> Hyperglycaemia and hyperlipidaemia combined play a role in the pathogenesis of vascular dysfunction. In human endothelial cells, high glucose concentrations induce apoptosis and overproduction of reactive oxygen species, leading to endothelial dysfunction.<sup>6 7</sup> Moreover, in humans, high insulin and TG concentrations have a synergistic association with arterial stiffness.<sup>8</sup> Additionally, the retinal venular calibre—a secondary marker of vascular dysfunction—is significantly

larger in people with increased fasting glucose levels and glycated haemoglobin (HbA1C).<sup>9</sup>

Arterial stiffness is an early marker of cardiovascular disease<sup>10</sup> and a strong predictor of future cardiovascular events.<sup>11</sup> The retinal arteriolar narrowing is associated with hypertension, especially when combined with higher venular diameter.<sup>12 13</sup> An increase in the arteriolar-to-venule diameter ratio (AVR) is associated with an increased risk of coronary heart disease and acute myocardial infarction in women.<sup>14</sup> Therefore, assessment of the retinal and central blood vessels allows the detection of early changes in vascular function, possibly prior to type 2 diabetes mellitus (T2DM) and its complications.

Given the current obesity epidemic, the WHO recommends reducing sugar intake.<sup>15</sup> A possibility to achieve this recommendation is to partially replace sugar with low-calorie sweeteners such as erythritol and xylitol. These sweeteners are interesting for patients with overweight and diabetes due to their low glycemic indexes<sup>16</sup> and their ability to induce the secretion of gastrointestinal satiation hormones.<sup>17–19</sup> Additionally, erythritol has a protective effect on endothelial cell function, as shown in endothelial cell culture as well as in patients with T2DM, and a 4-week intake reduces central pulse pressure in patients with T2DM.<sup>20 21</sup>


A recent study suggests a potential link between plasma erythritol levels and cardiovascular events in humans.<sup>22</sup> However, erythritol is also produced endogenously from glucose in humans.<sup>23</sup> In the studied group, the origin of erythritol is not clear, which makes a causal analysis impossible. Rodent studies hint that sucrose intake may raise internal erythritol production,<sup>24</sup> possibly explaining higher erythritol levels.

Xylitol has beneficial effects on visceral fat mass, plasma insulin, glycaemia and lipid concentrations in non-diabetic rats.<sup>25 26</sup> In humans, xylitol intake for 18 days tends to decrease cholesterol levels compared with 6-day sucrose intake.<sup>27</sup> Finally, both substances show beneficial effects on glycaemic control in both normoglycaemic and diabetic rats.<sup>28 29</sup> Therefore, these two substances seem promising in preventing vascular dysfunction and its underlying mechanisms, such as endothelial cell death, hyperlipidaemia and hyperglycaemia.

The objective of this study was to investigate the impact of a 5-week intake of erythritol and xylitol on vascular function (primary objective), abdominal fat and blood lipids, glucose tolerance, uric acid, hepatic enzymes, creatinine, gastrointestinal tolerance and dietary patterns (secondary objectives) in humans with obesity.

## METHODS

The study was conducted as a randomised, controlled trial and performed in accordance with the current version (V.2013) of the Declaration of Helsinki on medical research involving human subjects (<https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/>).



**Figure 1** Participants flowchart.

A total of 44 normoglycaemic participants with obesity were recruited via advertisement between November 2016 and January 2022. Exclusion criteria included any prior medical conditions, any surgery with major changes to the gastrointestinal tract, regular medications use, pregnancy or consumption of substances in abuse. Participants did not have any dietary restrictions or regular consumption of erythritol or xylitol. Two participants dropped out for personal reasons and were replaced, resulting in 42 participants who completed the study (see participants' flowchart in figure 1). The baseline characteristics for each group are presented in table 1.

The participants were randomly assigned—by a third person, using a computer-based randomisation system—to consume either 12g of erythritol, or 8g of xylitol dissolved in water three times a day (together with the main meals) for 5 weeks or to the control group (no substance) in a 1:1:1 ratio.

The first week of intervention was an adaptation period: one portion per day for 2 days, then two portions per day for 3 days, finally three portions per day for two last days. Then, participants went on with three daily portions for the remaining 4 weeks. Participants in the control group did not consume any substances. In the intervention groups, the trial was double-blind, meaning that the study participants and the study personnel were blinded concerning the type of substance consumed.

Erythritol and xylitol were purchased from Mithana GmbH (Zimmerwald, Switzerland). The duration of intervention and the dosage of erythritol were based on a previous pilot study of Flint *et al*,<sup>21</sup> which showed reduced central pulse pressure and improved endothelial function in patients with T2DM after a 4-week intake of 36g/day of erythritol. This quantity of erythritol is a feasible dosage to replace the daily added sugar intake in Switzerland and represents real-life conditions. Xylitol was given in an equisweet dosage to erythritol.

Before and after the intervention period, participants were invited to three study visits to assess arterial stiffness and retinal vessels diameters, abdominal fat quantification

**Table 1** Baseline characteristics (mean±SD) for each group

Parameter	Erythritol group	Xylitol group	Control group	P values
Sex	n=14 (8♂; 6♀)	n=14 (9♂; 5♀)	n=14 (7♂; 7♀)	0.583*
Age (years)	31.3±8.8	30.4±10.6	30.6±10.1	0.972†
BMI (kg/m <sup>2</sup> )	33.9±3.7	34.8±2.8	34.9±3.7	0.709†
Systolic blood pressure (mm Hg)	131.9±12.9	129.4±7.3	126.4±17.2	0.552†
Diastolic blood pressure (mm Hg)	85.9±10.9	85.6±10.2	78.7±8.6	0.107†
Pulse rate (1/min)	72.9±11.2	73.9±11.2	75.3±11.2	0.862†

♀: females, ♂: males.  
 \*Chi-square test.  
 †Analysis of variance.  
 BMI, body mass index.

(including subcutaneous, visceral and hepatic distribution), and glycaemic control, blood lipids, uric acid, hepatic enzymes and creatinine. In addition, gastrointestinal tolerance and dietary patterns were assessed before and during the second and fourth week of intervention. Further information on the methodology is found in online supplemental appendix S1.

### Statistical analysis

This study is a pilot trial. Therefore, a minimum number of 14 participants per group was chosen for reasons of comparability and practicability. Imputation of isolated missing values, which constituted less than 0.5% of the data set, except for glucose (3.3%), was performed using the median value corresponding to the respective treatment group. Therefore, the imputation did not alter the distribution of the values for the parameter in question.

For longitudinal parameters, a linear mixed effect model with subsequent Šidak test was applied using the time (pre- or post-intervention) as a within-subject factor and the treatment (erythritol, xylitol, control) as a fixed between-subject factor. Non-longitudinal parameters were analysed by general linear modelling. SPSS for Windows software, V.25.0 was used (IBM, Armonk, New York). Values are reported as mean±SD and displayed in figures as mean±SE of the mean (SEM) or median and IQR for boxplots. Differences were considered to be statistically significant when  $p < 0.05$ . For the primary

endpoint, effect sizes were calculated as Cohen's D with their corresponding 95% CIs in Python (V.3.11) using the modules Statsmodels (V.0.13.5)<sup>30</sup> and Scipy (V.1.10.1).

## RESULTS

### Vascular function: arterial stiffness, retinal vessel diameters

No statistically significant effect of erythritol or xylitol intake on vascular function was found. For arterial stiffness: Neither the time (preintervention or postintervention) nor the treatment (erythritol, xylitol, control) effects were significantly different for the left brachial pulse wave velocity (LB-PWV).

The effect size (Cohen's D (95% CI)) for the time effect was  $-0.14$  ( $-0.54$ – $0.25$ ), and the effect sizes (Cohen's D (95% CIs)) for the treatment effects were control versus xylitol:  $-0.11$  ( $-0.61$ – $0.35$ ), control versus erythritol:  $0.05$  ( $0.44$ – $0.54$ ) and erythritol versus xylitol:  $0.07$  ( $-0.41$ – $0.54$ ).

For retinal vessel diameters: neither the time nor the treatment effects were significantly different for the AVR. The effect size (Cohen's D (95% CI)) for the time effect was  $-0.14$  ( $-0.034$ – $0.01$ ), and the effect sizes (Cohen's D (95% CIs)) for the treatment effects were control versus xylitol:  $-0.23$  ( $-0.61$ – $0.26$ ), control versus erythritol:  $0.13$  ( $-0.11$ – $0.16$ ) and erythritol versus xylitol:  $0.12$  ( $0.10$ – $0.14$ ). The vascular parameters are reported in table 2.

**Table 2** Arterial stiffness and retinal vessel diameters (mean±SD) for each group before and after intervention

Parameter	Time point	Erythritol group	Xylitol group	Control group	Time effect (P value)	Treatment effect (P value)
LB-PWV(m/s)	Preintervention	(n=12) 6.0±0.9	(n=13) 6.1±0.9	(n=13) 5.9±0.9	0.079	0.792
	Postintervention	(n=12) 5.8±0.6	(n=13) 6.0±0.9	(n=12) 5.9±0.9		
AVR (n=14)	Preintervention	0.8±0.0	0.8±0.1	0.8±0.1	0.900	0.698
	Postintervention	0.8±0.0	0.8±0.1	0.8±0.1		

Linear mixed effect model with subsequent Šidak test.  
 AVR, arteriolar-to-venular diameter ratio; LB-PWV, left-brachial pulse wave velocity.

**Table 3** Abdominal fat and blood lipids parameters (mean±SD) for each group before and after intervention

Parameter	Time point	Erythritol group (n=14)	Xylitol group (n=14)	Control group (n=14)	Time effect (P value)	Treatment effect (P value)
Liver volume (L)	Preintervention	1.70±0.40	1.81±0.47	1.72±0.30	0.307	0.564
	Postintervention	1.70±0.47	1.89±0.52	1.70±0.32		
Liver fat percentage (%)	Preintervention	9.5±7.8	7.3±6.6	6.1±7.3	0.436	0.892
	Postintervention	8.7±7.6	7.3±7.5	6.0±6.5		
VAT volume (L)	Preintervention	4.64±2.62	3.98±1.85	4.21±1.53	0.216	0.583
	Postintervention	5.11±3.00	4.39±2.03	4.32±1.72		
SAT volume (L)	Preintervention	13.06±3.73	12.84±2.71	13.27±4.32	0.300	0.995
	Postintervention	12.96±4.22	13.07±2.71	13.48±4.57		
Triglycerides (mmol/L)	Preintervention	1.9±1.3	1.4±0.7	2.2±2.1	0.158	0.837
	Postintervention	1.6±1.0	1.7±1.0	1.2±0.5		
Total cholesterol (mmol/L)	Preintervention	5.4±1.4	4.8±0.9	4.7±1.0	0.489	0.365
	Postintervention	5.0±1.1	4.8±1.1	4.6±0.9		
HDL-cholesterol (mmol/L)	Preintervention	1.8±1.8	1.4±0.3	1.2±0.3	0.240	0.364
	Postintervention	1.3±0.4	1.3±0.2	1.2±0.3		
LDL-cholesterol (mmol/L)	Preintervention	3.0±0.9	3.0±0.5	3.1±0.7	0.038*	0.943
	Postintervention	2.9±0.7	2.9±0.6	2.9±0.9		

Linear mixed effect model with subsequent Šidak test.

\*Significant with  $p < 0.05$ .

HDL, high-density lipoprotein; LDL, low-density lipoprotein; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.

### Abdominal fat: quantification and distribution, blood lipids

No statistically significant effect of erythritol or xylitol intake on abdominal fat and blood lipids was found. Abdominal fat: neither the time nor the treatment effects were significantly different for the liver volume, the liver fat percentage, the visceral adipose tissue and the subcutaneous adipose tissue volumes.

Blood lipids: neither the time nor the treatment effects were significantly different for TGs, total cholesterol levels and high-density lipoprotein cholesterol. There was a significant time, but no treatment effect for the low-density lipoprotein (LDL) cholesterol. In all treatment groups, the LDL cholesterol levels were significantly decreased after the intervention compared with before. The respective parameters are reported in [table 3](#).


### Glucose tolerance

No statistically significant effect of erythritol or xylitol intake on glucose tolerance was found. Neither the time nor the treatment effects were significantly different for the glucose and insulin concentrations during oral glucose tolerance test (see [figure 2](#)), and for the areas under the glucose and insulin concentration curves at 120 min (glucose:  $p=0.482$  and  $p=0.412$ , respectively; insulin:  $p=0.902$  and  $p=0.583$ , respectively).


No statistically significant effect of erythritol or xylitol intake on the Homeostatic Model Assessment index = (fasting glucose × fasting insulin)/22.5 was found. Neither the time nor the treatment effects were significantly different ( $p=0.339$ ,  $p=0.780$ , respectively, see [figure 3](#)).

### Uric acid, hepatic enzymes and creatinine

No statistically significant effect of erythritol or xylitol intake on uric acid, hepatic enzymes and creatinine was found. Neither the time nor the treatment effects were significantly different for uric acid, aspartate



**Figure 2** Glucose and insulin concentrations during glucose tolerance test for each group before and after intervention (mean±SEM).



**Figure 3** HOMA Index for each group before and after intervention (median and IQR). HOMA, Homeostatic Model Assessment.

aminotransferase, alanine aminotransferase and creatinine. The respective parameters are reported in table 4.

**Gastrointestinal tolerance and dietary patterns**

Gastrointestinal Symptoms Rating Scale (GSRs)-Question 15 (sensation of not completely emptying the bowels) was removed from the analysis due to many missing values. Overall, the gastrointestinal tolerance was good. No statistically significant effect of erythritol or xylitol intake on abdominal pain, indigestion or constipation was found. Neither the time nor the treatment effects were significantly different for the GSRs questions regarding those symptoms. There was a significant treatment effect with regard to the experience of reflux (question 2: ‘Have you been bothered by heartburn during the past week (meaning retrosternal discomfort or unpleasant burning sensation in the chest)?’) and loose stools (question 12: ‘Have you been bothered by loose stools during the past week?’). In the control group, participants experienced significantly more reflux compared with the erythritol group, and in the xylitol group, participants have been significantly more bothered by loose stools compared with the erythritol group. In addition, there was a significant time effect with regard to sensations of an urgent need for bowel movement (question 14: ‘Have you been bothered by an urgent need to have a bowel movement during

the past week?’). In all treatment groups, the sensations of urgent need for bowel movement were significantly increased after the second week compared with preintervention. The mean scores of the different gastrointestinal symptoms are displayed in table 5.

For dietary pattern, there was a significant time, and a significant treatment effect regarding the consumption of dairy products. In all treatment groups, the consumption of dairy products was significantly reduced after the fourth week compared with preintervention (p=0.027). Additionally, in the erythritol group, participants consumed significantly more dairy products compared with the xylitol group (p=0.028). Otherwise, there was only a significant time, but no treatment effect on the consumption of beverages with added sugar (preintervention vs week 2, p=0.024, and preintervention vs week 4, p=0.048), sugar-sweetened beverages (preintervention vs week 4, p=0.025) and sweets (preintervention vs week 2, p=0.001, and preintervention vs week 4, p=0.022). In all treatment groups, the consumption of beverages with added sugar, sugar-sweetened beverages and sweets was significantly reduced compared with preintervention.

**DISCUSSION**

In this randomised controlled trial, we examined the effect of a 5-week intake of erythritol and xylitol on vascular function, abdominal fat and glucose tolerance in humans with obesity. Additionally, we examined blood lipids, uric acid, hepatic enzymes and creatinine, assessed gastrointestinal symptoms and evaluated changes in dietary patterns.

Flint *et al*<sup>21</sup> found a significant decrease in central pulse pressure and a trend for reduced PWV after a 4-week erythritol intake in patients with T2DM.<sup>21</sup> Our study found no statistically significant effect of erythritol and xylitol intake on vascular function (PWV and retinal vessel diameters) in normoglycaemic participants with obesity. This discrepancy may be due to differences in the study populations, as participants with T2DM typically

**Table 4** Uric acid, hepatic enzymes and creatinine (mean±SD) for each group before and after intervention

Parameter	Time point	Erythritol group (n=14)	Xylitol group (n=14)	Control group (n=14)	Time effect (P value)	Treatment effect (P value)
Uric acid(mmol/L)	Preintervention	350.5±84.6	391.2±108.3	342.1±70.5	0.704	0.330
	Postintervention	342.9±77.4	380.6±92.4	351.9±60.2		
ASAT(U/L)	Preintervention	22.0±9.7	25.9±14.5	23.1±10.5	0.436	0.876
	Postintervention	25.6±11.7	25.7±13.0	22.3±7.3		
ALAT(U/L)	Preintervention	38.4±19.4	33.6±22.6	31.1±23.5	0.800	0.518
	Postintervention	40.5±26.9	32.2±17.9	28.6±16.1		
Creatinine (mmol/L)	Preintervention	69.3±21.8	72.9±13.0	70.8±12.9	0.611	0.491
	Postintervention	69.3±13.0	70.1±14.5	70.7±13.8		

Linear mixed effect model with subsequent Šidak test. ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase.

**Table 5** Gastrointestinal symptoms scores (mean±SD) for each group before and after intervention

Parameter	Time point	Erythritol group (n=14)	Xylitol group (n=14)	Control group (n=14)	Time effect (P value)	Treatment effect (P value)
Q1: Abdominal pain (pain or discomfort in the upper abdomen)	Preintervention	1.2±0.4	1.4±0.9	1.1±0.4	0.108	0.390
	Week 2 of intervention	1.6±1.6	1.6±1.1	1.8±0.9		
	Week 4 of intervention	1.3±0.8	1.6±1.0	1.9±1.4		
Q2: Reflux (heart burn)	Preintervention	1.1±0.4	1.7±1.3	1.4±0.6	0.560	0.015* (C vs E)
	Week 2 of intervention	1.3±0.5	1.5±0.9	1.3±0.6		
	Week 4 of intervention	1.1±0.5	1.6±1.0	1.8±1.2		
Q3: Reflux (acid reflux)	Preintervention	1.1±0.4	1.4±1.1	1.4±0.8	0.872	0.531
	Week 2 of intervention	1.4±0.7	1.3±0.6	1.2±0.4		
	Week 4 of intervention	1.3±0.8	1.2±0.6	1.6±0.9		
Q4: Abdominal pain (hunger pains)	Preintervention	1.9±0.9	2.7±1.4	2.2±1.5	0.813	0.141
	Week 2 of intervention	2.1±1.4	2.7±1.4	2.6±1.5		
	Week 4 of intervention	1.8±1.1	2.6±1.3	2.2±1.0		
Q5: Abdominal pain (nausea)	Preintervention	1.0±0.0	1.4±0.8	1.3±0.7	0.261	0.480
	Week 2 of intervention	1.6±1.4	1.5±1.2	1.2±0.4		
	Week 4 of intervention	1.3±0.8	1.7±1.3	1.6±1.0		
Q6: Indigestion (rumbling in the stomach)	Preintervention	1.8±1.1	2.2±1.1	2.0±1.6	0.170	0.113
	Week 2 of intervention	1.7±0.9	2.5±1.3	2.6±1.7		
	Week 4 of intervention	1.4±0.6	2.6±1.8	1.8±1.3		
Q7: Indigestion (bloating)	Preintervention	2.5±1.8	2.4±1.5	2.1±1.4	0.807	0.442
	Week 2 of intervention	2.1±1.9	2.8±1.9	2.2±1.4		
	Week 4 of intervention	1.7±1.1	2.7±1.8	2.4±1.9		
Q8: Indigestion (burping)	Preintervention	1.6±0.8	2.1±1.3	1.9±1.2	0.436	0.079
	Week 2 of intervention	1.5±0.9	1.9±1.3	2.0±1.3		
	Week 4 of intervention	1.3±0.6	2.1±1.4	2.5±2.0		
Q9: Indigestion (passing gas/flatus)	Preintervention	2.4±1.4	2.9±1.4	2.5±1.1	0.935	0.482
	Week 2 of intervention	2.6±1.7	2.9±1.7	2.4±1.5		
	Week 4 of intervention	2.2±1.2	2.9±1.9	2.8±1.9		
Q10: Constipation (reduced emptying)	Preintervention	1.0±0.0	1.5±1.3	2.1±1.4	0.701	0.159
	Week 2 of intervention	1.6±1.3	1.8±1.5	1.6±0.9		
	Week 4 of intervention	1.1±0.5	2.0±1.9	1.5±1.2		
Q11: Diarrhoea (frequent emptying)	Preintervention	1.4±0.7	1.6±0.9	1.9±1.0	0.212	0.236
	Week 2 of intervention	1.9±1.2	2.4±1.7	1.2±0.6		
	Week 4 of intervention	1.7±0.8	2.1±1.6	2.3±1.3		
Q12: Diarrhoea (loose stools)	Preintervention	1.4±0.9	1.6±0.9	2.1±1.2	0.297	0.022* (E vs X)
	Week 2 of intervention	1.4±0.6	2.9±2.1	1.5±0.8		
	Week 4 of intervention	1.5±0.8	2.5±2.0	2.4±1.8		
Q13: Constipation (hard stools)	Preintervention	1.2±0.8	1.7±1.4	1.9±1.3	0.563	0.630
	Week 2 of intervention	1.9±1.4	1.4±0.9	1.9±1.3		
	Week 4 of intervention	1.4±0.6	1.9±1.2	1.4±0.8		
Q14: Diarrhoea (urgent need of bowel movement)	Preintervention	1.4±0.5	1.1±0.5	1.4±0.6	0.006** (pre vs W2)	0.262
	Week 2 of intervention	1.6±0.9	2.7±1.9	1.5±0.8		
	Week 4 of intervention	1.6±1.0	2.4±2.2	2.1±1.8		
Q15: Diarrhoea (incomplete emptying)	<i>Removed from the analysis due to many missing values</i>					
Linear mixed effect model with subsequent Šidak test.						
**Significant with p<0.01; *significant with p<0.05.						
C, control group; E, erythritol group; W2, week 2; X, xylitol group.						

have higher PWV compared with healthy individuals.<sup>31</sup> Participants in our study were, considering a clinically healthy upper limit for PWV of 10 m/s,<sup>32 33</sup> already in the normal range before the intervention. However, even if erythritol and xylitol consumption did not improve vascular function in our trial, the fact that their ingestion showed no statistically significant effect concerning vascular function in our population argues for their use as a sugar substitutes, as hyperglycaemia associated with sugar intake is known to impact vascular function.<sup>34</sup> Of note, a recent cohort study by Witkowski *et al*<sup>22</sup> showed a possible correlation between erythritol blood levels and risk of cardiovascular events in humans. Given that erythritol is also endogenously synthesised in humans via the pentose-phosphate pathway from glucose,<sup>23</sup> determining the source of erythritol in this particular group remains uncertain, making it impossible to establish a causal relationship. Interestingly, studies on rodents suggest that sucrose intake can stimulate the endogenous production of erythritol.<sup>24</sup> Consequently, the observed high plasma erythritol levels could potentially be attributed to heightened sugar consumption.

Amo *et al*<sup>25</sup> found that in rats fed a high-fat diet and receiving xylitol during 8 weeks, visceral fat mass was significantly lower compared with the control group.<sup>25</sup> In our trial, the 5-week intake of erythritol and xylitol showed no statistically significant effect on abdominal fat mass and its distribution. Of note, participants were instructed to consume their habitual diet, and, therefore, did not profit from the possible beneficial effect of xylitol found when combined with a high-fat diet. Our results concerning blood lipids are in line with a human study looking at an intake of high doses (up to 100g/day, during 18 days) of xylitol in healthy volunteers, which found no changes in TG levels and a trend in reduction of cholesterol levels.<sup>27</sup> Therefore, erythritol and xylitol seem superior compared with sucrose, which is known to increase blood lipids and promote liver fat accumulation.<sup>35 36</sup>

Huttunen *et al*<sup>37</sup> found no effect of chronic xylitol intake (30g/day) for 2 years on fasting insulin or glucose concentrations in healthy volunteers.<sup>37</sup> In line, we also found no statistically significant effect of a 5-week erythritol or xylitol intake on glucose tolerance. However, in another study assessing the effect of 20g/day erythritol during 2 weeks on glucose tolerance in patients with T2DM, Ishikawa *et al*<sup>38</sup> found a trend for decreased fasting blood glucose and decreased HbA1C.<sup>38</sup> Here again, the difference in study populations might explain the discrepancy. In conclusion, we show that erythritol and xylitol do not lead to statistically significant changes in glucose tolerance, which make them promising sugar alternatives, especially in patients at risk for T2DM.

We have previously found that acute ingestion of 35g xylitol led to an increase in uric acid, while there was no effect after 50g erythritol.<sup>18 19</sup> An increase in uric acid was also found in an acute study in healthy volunteers given 35g xylitol during physical exercise.<sup>39</sup> Förster *et al*<sup>27</sup> reported that plasma uric acid was unchanged in

healthy volunteers after 18 days of up to 100g/day xylitol consumption. Here, we did not find any statistically significant elevation in uric acid in either group. We conclude that an increase in uric acid can be observed when xylitol is given acutely in healthy volunteers, but not after a 5-week exposure in volunteers with obesity but without T2DM.

Gastrointestinal tolerance in our trial was good except for a few diarrhoea-related symptoms at the beginning of the intervention, especially in the xylitol group. This is in line with other studies, showing that the acute consumption of xylitol might cause some gastrointestinal inconvenience,<sup>19 39</sup> and that subjects over time adapt to chronic intake.<sup>40</sup>

There were some modifications in dietary patterns during the intervention. Participants of all treatment groups reduced their consumption of dairy products, sweetened beverages and sweets compared with preintervention. However, as these changes also occurred in participants of the control group, we rather interpret them as a 'study effect' than any intervention effect.

It is necessary to acknowledge some limitations of this study. First, as this is a pilot study, we cannot exclude that the sample size has been too small to detect significant changes. Second, the duration of intake was only 5 weeks. Therefore, no conclusions can be drawn for longer periods. Third, as no placebo substance is available, which would be metabolically inert and sweet in taste, the study was not placebo-controlled. Therefore, participants in the control group were not blinded. Fourth, no biomarker of intake was assessed, therefore compliance to the study intervention could not be objectively measured. Fifth, the participants consumed 36g/day, or 24g/day of erythritol or xylitol, respectively. Therefore, we cannot exclude that the use of higher amounts of erythritol and xylitol would have induced an effect on the parameters studied. However, higher dosages might cause more severe gastrointestinal symptoms, leading to poorer treatment adherence, and might not represent real-life settings.

In conclusion, we showed that the 5-week intake of erythritol and xylitol in people with obesity had no statistically significant effects on vascular function, abdominal fat and blood lipids, glucose tolerance, uric acid, hepatic enzymes and creatinine and was well tolerated except loose stools in the xylitol group. These results are relevant given the current recommendation to reduce sugar consumption, as the dosages and intake time points correspond to everyday-life sugar consumption. The study adds important information to the knowledge about erythritol and xylitol, showing that they are promising sugar alternatives, especially for people with obesity and, therefore, at risk of hypertension and cardiovascular diseases, hepatic steatosis and type 2 diabetes.

#### Author affiliations

<sup>1</sup>Metabolic Research Group, St. Clara Research Ltd, Basel, Switzerland

<sup>2</sup>Department of Clinical Research, Faculty of Medicine, University of Basel, Basel, Switzerland

<sup>3</sup>Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland

<sup>4</sup>Department of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland  
<sup>5</sup>Department for Sport, Exercise and Health, University of Basel, Basel, Switzerland

**Acknowledgements** We would like to thank V. Rahmel, C. Cudré-Mauroux, K. Roser (students), A. Etter-Atlass, D. Brosi, J. Brosi and S. Gagliardo (study nurses), Dr. L. Streese (sport scientist) and C. Hauser (PhD Student) for their help in the current study.

**Contributors** OB, AS-T, HH, CB, ACM-G and BKW designed the research. VB, FT and PM conducted the research. JD performed the statistical analysis. VB wrote the paper. ACM-G and BKW are responsible for the overall content as guarantors. All authors have read and approved the final manuscript.

**Funding** This work was supported by: 'Freiwillige Akademische Gesellschaft' and 'Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung'. Grant receiver: ACM-G.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** The protocol was approved by the Ethikkommission Nordwest- und Zentralschweiz: 2016-00781. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Data described in the manuscript will be made available upon request to the corresponding author.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Valentine Bordier <http://orcid.org/0000-0002-1229-825X>

## REFERENCES

- Meyer-Gerspach AC, Wölnerhanssen B, Beglinger B, *et al*. Gastric and intestinal satiation in obese and normal weight healthy people. *Physiol Behav* 2014;129:265–71.
- Nguyen NQ, Debrececi TL, Bambrick JE, *et al*. Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, Incretin hormones, and Glycemia. *J Clin Endocrinol Metab* 2015;100:968–76.
- Seimon RV, Brennan IM, Russo A, *et al*. Gastric emptying, mouth-to-cecum transit, and glycemic, insulin, Incretin, and energy intake responses to a mixed-nutrient liquid in lean, overweight, and obese males. *Am J Physiol Endocrinol Metab* 2013;304:E294–300.
- Mavrelis PG, Ammon HV, Gleysteen JJ, *et al*. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. *Hepatology* 1983;3:226–31.
- Lee Y, Hirose H, Zhou Y-T, *et al*. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. *Diabetes* 1997;46:408–13.
- Risso A, Mercuri F, Quagliaro L, *et al*. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. *Am J Physiol Endocrinol Metab* 2001;281:E924–30.
- Tsuneki H, Sekizaki N, Suzuki T, *et al*. Coenzyme Q10 prevents high glucose-induced oxidative stress in human umbilical vein endothelial cells. *Eur J Pharmacol* 2007;566:1–10.
- Salomaa V, Riley W, Kark JD, *et al*. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. *Circulation* 1995;91:1432–43.
- Nguyen TT, Wang JJ, Sharrett AR, *et al*. Relationship of retinal vascular caliber with diabetes and retinopathy: the multi-ethnic study of atherosclerosis (MESA). *Diabetes Care* 2008;31:544–9.
- Franklin SS. Beyond blood pressure: arterial stiffness as a new biomarker of cardiovascular disease. *J Am Soc Hypertens* 2008;2:140–51.
- Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol* 2010;55:1318–27.
- Ikram MK, Wittman JCM, Vingerling JR, *et al*. Retinal vessel diameters and risk of hypertension the Rotterdam study. *Hypertension* 2006;47:189–94.
- Streese L, Lona G, Wagner J, *et al*. Normative data and standard operating procedures for static and dynamic retinal vessel analysis as biomarker for cardiovascular risk. *Sci Rep* 2021;11:14136.
- Wong TY, Klein R, Sharrett AR, *et al*. Retinal arteriolar narrowing and risk of coronary heart disease in men and women the atherosclerosis risk in communities study. *JAMA* 2002;287:1153–9.
- WHO. *Guideline: sugars intake for adults and children*. Geneva: World Health Organization, 2015.
- Livesey G. Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties. *Nutr Res Rev* 2003;16:163–91.
- Wölnerhanssen BK, Cajacob L, Keller N, *et al*. Gut hormone secretion, gastric emptying, and glycemic responses to erythritol and xylitol in lean and obese subjects. *Am J Physiol Endocrinol Metab* 2016;310:E1053–61.
- Wölnerhanssen BK, Drewe J, Verbeure W, *et al*. Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: a pilot dose-ranging study. *Diabetes Obes Metab* 2021;23:1311–21.
- Meyer-Gerspach AC, Drewe J, Verbeure W, *et al*. Effect of the natural sweetener xylitol on gut hormone secretion and gastric emptying in humans: a pilot dose-ranging study. *Nutrients* 2021;13:174.
- Boesten D, Berger A, de Cock P, *et al*. Multi-targeted mechanisms underlying the endothelial protective effects of the diabetic-safe sweetener erythritol. *PLoS One* 2013;8:e65741.
- Flint N, Hamburg NM, Holbrook M, *et al*. Effects of erythritol on endothelial function in patients with type 2 diabetes mellitus: a pilot study. *Acta Diabetol* 2014;51:513–6.
- Witkowski M, Nemet I, Alamri H, *et al*. The artificial sweetener erythritol and cardiovascular event risk. *Nat Med* 2023;29:710–8.
- Hootman KC, Trezzi J-P, Kraemer L, *et al*. Erythritol is a pentose-phosphate pathway metabolite and associated with adiposity gain in young adults. *Proc Natl Acad Sci U S A* 2017;114:E4233–40.
- Ortiz SR, Field MS. Sucrose intake elevates erythritol in plasma and urine in male mice. *J Nutr* 2023;153:1889–902.
- Amo K, Arai H, Uebanso T, *et al*. Effects of xylitol on metabolic parameters and visceral fat accumulation. *J Clin Biochem Nutr* 2011;49:1–7.
- Kishore P, Kehlenbrink S, Hu M, *et al*. Xylitol prevents NEFA-induced insulin resistance in rats. *Diabetologia* 2012;55:1808–12.
- Förster H, Quadbeck R, Gottstein U. Metabolic tolerance to high doses of oral xylitol in human volunteers not previously adapted to xylitol. *Int J Vitam Nutr Res Suppl* 1982;22:67–88.
- Islam MS. Effects of xylitol as a sugar substitute on diabetes-related parameters in nondiabetic rats. *J Med Food* 2011;14:505–11.
- Msomi NZ, Erukainure OL, Salau VF, *et al*. Comparative effects of xylitol and erythritol on modulating blood glucose; inducing insulin secretion; reducing dyslipidemia and redox imbalance in a type 2 diabetes rat model. *Food Science and Human Wellness* 2023;12:2052–60.
- Seabold S, Perktold J. Statsmodels: econometric and statistical modeling with python. Python in Science Conference; Austin, Texas.2010
- Prenner SB, Chirinos JA. Arterial stiffness in diabetes mellitus. *Atherosclerosis* 2015;238:370–9.
- Mancia G, Fagard R, Narkiewicz K, *et al*. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013;31:1281–357.
- Koivisto T, Kööbi T, Jula A, *et al*. Pulse wave velocity reference values in healthy adults aged 26–75 years. *Clin Physiol Funct Imaging* 2007;27:191–6.
- Kobayashi R, Sakazaki M, Nagai Y, *et al*. Effects of different types of carbohydrates on arterial stiffness: a comparison of Isomaltulose and Sucrose. *Nutrients* 2021;13:4493.





- 35 Geidl-Flueck B, Hochuli M, Németh Á, *et al.* Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial. *J Hepatol* 2021;75:46–54.
- 36 Marckmann P, Raben A, Astrup A. Ad libitum intake of low-fat diets rich in either starchy foods or sucrose: effects on blood lipids, factor VII coagulant activity, and fibrinogen. *Metabolism* 2000;49:731–5.
- 37 Huttunen JK, Mäkinen KK, Scheinin A. Turku sugar studies XI: effects of sucrose, fructose and xylitol diets on glucose, lipid and Urate metabolism. *Acta Odontol Scand* 1976;34:345–51.
- 38 Ishikawa M, Miyashita M, Kawashima Y, *et al.* Effects of oral administration of erythritol on patients with diabetes. *Regul Toxicol Pharmacol* 1996;24:S303–8.
- 39 Wołyniec W, Szwarc A, Kasproicz K, *et al.* Impact of hydration with beverages containing free sugars or xylitol on metabolic and acute kidney injury markers after physical exercise. *Front Physiol* 2022;13:841056.
- 40 Scheinin A, Mäkinen KK. Turku sugar studies: an overview. *Acta Odontol Scand* 1976;34:405–8.

1 ***Appendix S1: Detailed description of the experimental procedure, the assessment of***  
2 ***parameters, and the laboratory analyses***

3

4 *Assessment of vascular function: arterial stiffness, retinal vessel diameters*

5 Before and after the intervention period, participants were admitted to the Department of  
6 Sport, Exercise and Health of the University of Basel to assess arterial stiffness and retinal  
7 vessel diameters. To prepare for the measurements, participants were instructed to abstain  
8 from caffeine, alcohol and heavy physical activity, and to fast at least four hours.

9 Arterial stiffness was measured oscillometrically using a VaSera VS-1500 vascular screening  
10 system (Fukuda Denshi Co. Ltd, Tokyo, Japan). Triple measurements were taken in a supine  
11 position after resting for at least 10 minutes and 5 minutes between the measurements in a  
12 quiet room with a controlled temperature between 22-24 °C. Standard blood pressure cuffs  
13 were placed at each upper arm and above each ankle. Electrocardiogram leads were attached  
14 at each wrist, and a phonocardiogram was placed on the sternal border in the second  
15 intercostal space. The heart-ankle pulse wave velocity (PWV) was measured based on the  
16 vessel length between the heart valve and the ankle artery divided by the time taken for the  
17 pulse wave to propagate from the aortic valve to the ankle. ARCSolver algorithm was applied  
18 to pulse wave signals acquired at the left upper arm to estimate central PWV (1). The average  
19 of the three PWV-measurements was taken for statistical analysis.

20 A fundus camera (Topcon TRC NW) and the analyzing software Visualis (Visualis 2.80,  
21 Imedos Systems UG) were used for retinal image acquisition. Three crisp images of each eye  
22 were taken at an angle of 45 degrees with the optic disc at the center. All arterioles and  
23 venules 0.5–1 disk diameter away from the optic disk margin were marked. Retinal arteriolar  
24 and venular diameter segments were semi-automatically marked using an analysis software  
25 (Vesselmap 2®; IMEDOS Systems GmbH, Jena, Germany). Arteriolar and venular diameters

26 from the three images of each eye were averaged to Central Retinal Arteriolar Diameter  
27 Equivalents (CRAE) and Central Retinal Venular Diameter Equivalents (CRVE) by use of the  
28 Parr–Hubbard formula (2). The arteriolar-to-venular diameter ratio (AVR) was calculated  
29 from the CRAE and CRVE. The values of each eye were again averaged. To guarantee  
30 optimal standardization, the same vessel segments were chosen at both time points using the  
31 pre-intervention assessment as a reference.

32

### 33 *Assessment of abdominal fat: quantification and distribution*

34 Before and after the intervention period, participants were admitted to the Department of  
35 Radiology and Nuclear Medicine of the University Hospital of Basel for an abdominal MRI.  
36 Data for the evaluation of percentage liver fat (%-LF), total liver volume (TLV), visceral  
37 adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were acquired using a  
38 MAGNETOM Prisma 3T scanner (Siemens Healthineers, Erlangen, Germany). A transversal  
39 T2\*-IDEAL (3D spoiled gradient echo with 6 echoes) sequence was used for the liver fat  
40 measurement, and a two-point Dixon (3D spoiled gradient echo with two echoes) sequence in  
41 coronal orientation for the SAT and VAT quantification. Both scans were performed in breath  
42 holding (up to 20 seconds each). Details on data acquisition and evaluation are described  
43 elsewhere (3). In short, the T2\*-IDEAL scan covered the whole liver. Those images were  
44 segmented manually to derive %-LF and TLV. The two-point Dixon scan was used for the  
45 automatic SAT and VAT volume segmentation which was subsequently manually corrected,  
46 and spatially confined to the upper end of the femoral head and the lower end of the ninth  
47 thoracic vertebra.

48

### 49 *Assessment of glucose tolerance, blood lipids, uric acid, hepatic enzymes, and creatinine*

50 Before and after the intervention period, participants were admitted to the St. Clara Research

51 Ltd. in the morning after an overnight fast for an oral glucose tolerance test (OGTT). For this  
52 purpose, they were instructed to abstain from heavy physical activity within the two days  
53 before the test, to eat meals containing carbohydrates, and to come on an empty stomach, i.e.,  
54 not eat or drink (water allowed until two hours before the test) nor consume alcohol within ten  
55 hours before the test.

56 An antecubital catheter was inserted into a forearm vein for blood collection. After taking a  
57 fasting blood sample (t = -15 min) for assessment of fasting glucose and insulin  
58 concentrations (ethylenediaminetetraacetic acid (EDTA) tubes), blood lipids, uric acid,  
59 hepatic enzymes, creatinine concentrations (lithium heparin tubes), participants received a  
60 standardized solution containing 75 g of glucose.

61 Blood samples were taken at regular time intervals after administration of the solution (t = 30,  
62 60, 90, and 120 min) for assessment of glucose and insulin concentrations. The samples were  
63 collected on ice into tubes (EDTA, 6 µmol/L blood). After centrifugation (4 °C at 3000 rpm  
64 for 10 min), plasma samples were immediately processed into different aliquots and stored at  
65 -80 °C until analysis.

66

#### 67 *Assessment of gastrointestinal tolerance and dietary patterns*

68 Gastrointestinal tolerance was assessed using the Gastrointestinal Symptom Rating Scale  
69 (GSRS) (4) before and during the second and fourth week of intervention. The 15 items of  
70 this scale combine into five symptom clusters: reflux, abdominal pain, indigestion, diarrhea  
71 and constipation.

72 To assess changes in dietary patterns, participants completed dietary records seven days  
73 before the intervention and during the second and the fourth week of the intervention. The  
74 dietary records were analyzed qualitatively by categorizing the foods into 11 different groups  
75 (vegetables, fruits, cereals/bread, other carbohydrates, meat/fish/other protein sources, dairy

76 products, fats/nuts/seeds, beverages with added sugar (e.g., coffee with sugar), beverages with  
77 sweeteners, sugar-sweetened beverages, and sweets) and comparing the number of servings  
78 per food group.

79

#### 80 *Laboratory analysis*

81 Plasma glucose was measured by a glucose oxidase method (Rothen Medizinische  
82 Laboratorien AG, Basel, Switzerland; range of assay, 0.6 to 45.0 mmol/L). Plasma insulin  
83 was quantified using an electro-chemiluminescent immunoassay (Rothen Medizinische  
84 Laboratorien AG, Basel, Switzerland; range of assay, 4.0 to 1000.0 mIU/L; intra- and inter-  
85 assay variability below 4.3% and 5.3%).

86 The laboratory of the St. Clara Hospital in Basel assessed fasting blood lipids, uric acid,  
87 hepatic enzymes, and creatinine. Serum blood lipids (serum triglyceride, cholesterol, and high  
88 density lipoprotein (HDL)) were measured with enzymatic colorimetric tests. The intra- and  
89 inter-assay variability are below 2.1% and 2.3% (triglyceride), 2.1% and 7.4% (cholesterol),  
90 and 1.1% and 1.5% (HDL). Low density lipoprotein (LDL) was calculated with the  
91 Friedewald-Formula (5). Serum uric acid was measured with an enzymatic colorimetric test  
92 with an intra- and inter-assay variability below 1.7% and 2.0%. Hepatic enzymes alanine  
93 aminotransferase (ALAT) and aspartate aminotransferase (ASAT) were measured with  
94 enzymatic colorimetric tests. The intra- and inter-assay variability are below 1.8% and 1.8%  
95 (ALAT), and 1.6% and 1.8% (ASAT). Creatinine was assessed with a kinetic colorimetric test  
96 based on the Jaffe method (6) with an intra- and inter-assay variability below 2.9% and 3.4%.

97

98 **References**

- 99 1. Endes S, Bachler M, Li Y, Mayer C, Hanssen H, Hametner B, et al. Feasibility of oscillometric  
100 aortic pressure and stiffness assessment using the VaSera VS-1500: comparison with a common  
101 tonometric method. *Blood Press Monit.* 2015;20(5):273-9. Epub 2015/06/13. doi:  
102 10.1097/MBP.000000000000137. PubMed PMID: 26065840.
- 103 2. Hubbard LD, Brothers R, King WN, Clegg LX, Klein R, Cooper LS, et al. Methods for evaluation  
104 of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis  
105 Risk in Communities Study. *Ophthalmology.* 1999;106(2):2269-80.
- 106 3. Meyer-Gerspach AC, Peterli R, Moor M, Madorin P, Schotzau A, Nabers D, et al.  
107 Quantification of Liver, Subcutaneous, and Visceral Adipose Tissues by MRI Before and After Bariatric  
108 Surgery. *Obes Surg.* 2019;29(9):2795-805. Epub 2019/05/16. doi: 10.1007/s11695-019-03897-2.  
109 PubMed PMID: 31089967; PubMed Central PMCID: PMC6713693.
- 110 4. Svelund J, Sjodin I, Dotevall G. GSRs: A Clinical Rating Scale for Gastrointestinal Symptoms in  
111 Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease. *Digestive Diseases and Sciences.*  
112 1988;33(2):129-34.
- 113 5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density  
114 lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical Chemistry.*  
115 1972;18(6):499-502.
- 116 6. Jaffe M. Über den Niederschlag, welchen Pikrinsäure in normalem Harn erzwingt und über  
117 eine neue Reaction des Kreatinins. *Zeitschrift für physiologische Chemie.* 1886;10(5):391-400.

118